NCT03878199 2025-09-15
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
Clinical Trials
10 trialsNCT00061945 2022-05-03
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00850382 2016-03-01
Dasatinib (Sprycelâ„¢) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
University of Ulm
Phase 1/2 Completed
NCT00742625 2014-09-12
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00015860 2013-06-24
STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00005942 2013-01-23
Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00002925 2012-11-30
Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00005793 2012-09-25
A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00840684 2011-05-13
Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00129168 2008-04-01
Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)
Kanisa Pharmaceuticals
Phase 1/2 Completed